Connect your AI

PTHS PTHS Research and Development operations — Total Revenue

Other segment segments

Commercial operations

$10.67M—

Similar metrics at other companies

AMP

AMPHResearch And Development Services — Revenue

$2.5M+2,400%

RCUSR&D services — Total revenues

$2M0.0%

FSIResearch And Development Sales — Revenue

$625K—

KOPNResearch And Development — Revenue

$1.29M+4.3%

SIGAResearch And Development — Revenue

$2.7M+122%

KOPNResearch And Development Revenues — Revenue

$1.29M+4.3%

Other financials

Income statement

Revenue$10.9M—

Gross profit$9.2M—

Operating income-$13.1M-614%

Net income-$10.2M-420%

EPS (diluted)-$3.09+3.7%

Balance sheet

Cash & equivalents$32.0M+24,250%

Total debt$29.6M—

Total equity$35.1M+937%

Total assets$145.4M+15,855%

Cash flow

Operating cash flow-$13.1M-1,977%

CapEx$194.0K—

Free cash flow-$13.3M-2,008%

Valuation

Market cap$98.22M+92.4%

Enterprise value$95.89M—

P/S3.6×—

Profitability

Gross margin79.6%—

Operating margin-157.7%—

Net margin-186.2%—

FCF margin-60.8%—

Returns & leverage

Return on equity-333.8%—

Debt / equity0.8×—

Current ratio2.8×+2.6×

Where this comes from

Reported directly by PTHS in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: PTHS’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTHS's research and development operations — total revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is PTHS's research and development operations — total revenue?: PTHS (PTHS) reported research and development operations — total revenue of $241K in Q1 2026.
What does research and development operations — total revenue mean?: Represents the total gross income generated specifically from the research and development business segment. This metric tracks revenue streams derived from clinical-stage activities, such as licensing, research collaborations, or early-stage therapeutic partnerships. It serves as an indicator of the segment's ability to monetize its scientific intellectual property before full commercialization.